Frontiers in Clinical Drug Research – Anti Allergy Agents

Volume: 1

Indexed in: EBSCO, Scopus.

Frontiers in Clinical Drug Research - Anti-Allergy Agents is an exciting eBook series comprising a selection of updated review articles relevant to the recent development of pharmacological agents ...
[view complete introduction]

US $
30

*(Excluding Mailing and Handling)



New Therapies for Asthma: What Else Besides Steroids?

Pp. 24-49 (26)

Jorge Sánchez and Javier Estarita

Abstract

Allergic disorders are a group of multifactorial diseases increasing in prevalence in recent years. Steroids remain the cornerstone of symptomatic treatment, but advances in molecular biology have led to a better understanding of the pathogenesis of allergic diseases and multiple medications; especially monoclonal antibodies have been developed with different therapeutic targets.

Omalizumab (Anti-IgE) and mepolizumab (Anti-IL5) are some of the biological agents already available for the treatment of asthma and other allergic diseases, but many other molecules are currently being studied in clinical trials. In this chapter we review the different monoclonal antibodies that are being studied in allergic diseases with emphasis on the evidence of their use in asthma.

Keywords:

Asthma, allergy, allergen, immunotherapy, immunomodulation, monoclonal antibodies, mepolizumab, omalizumab, immunoglobulin, sensitization.

Affiliation:

GACE, Group of Clinical and Experimental Allergy, University of Antioquia, (Medellín - Colombia).